(Q21261900)

Dimensions

20 August 2022

Sandra Sostarich

series ordinal

2

author given names

Sandra

author last names

Sostarich

1 reference

Dimensions

20 August 2022

Richard W McCallum

series ordinal

3

author given names

Richard W

author last names

McCallum

1 reference

Dimensions

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

20 August 2022

language of work or name

English

0 references

publication date

22 February 2010

0 references

1 reference

10

0 references

issue

1

0 references

page(s)

23

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Use and abuse of hydrogen breath tests

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

The burden of illness of irritable bowel syndrome: current challenges and hope for the future

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Review article: proton pump inhibitors and bacterial overgrowth

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier?

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

The pathogenesis of gastrointestinal bacterial overgrowth

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

AGA technical review on irritable bowel syndrome

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

The impact of irritable bowel syndrome on health-related quality of life

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-10-23

Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-10-23

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-10-23

Small intestinal bacterial overgrowth and irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-10-23

Effect of tegaserod on gut transit in male and female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-10-23

Small bowel bacterial overgrowth is not seen in healthy adults but is in disabled older adults.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Impairment in work productivity and health-related quality of life in patients with IBS.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Evidence-based position statement on the management of irritable bowel syndrome in North America

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838757

Total costs of IBS: employer and managed care perspective

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20175924

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Small bowel bacterial overgrowth. An underrecognized cause of malnutrition in older adults

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20175924

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-230X-10-23

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

924693

OpenCitations bibliographic resource ID

0 references

924693

1 reference